Exact Mass: 555.2468
Exact Mass Matches: 555.2468
Found 500 metabolites which its exact mass value is equals to given mass value 555.2468
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Oxyapramycin
Butirosin B
A butirosin that consists of neamine in which is substituted at position 2 by a beta-D-ribofuranosyl and at position 4 by an (S)-2-hydroxy-4-aminobutyryl group. D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents
Enkephalin L
Enkephalin L is an opioid peptide. Opioid peptides are a group of neuropeptides which include enkephalins, endorphins and dynorphins. In addition to their central and peripheral antinociceptive function, opioids can modulate immune activity and cell proliferation. Enkephalins typically have a turnover rate measured in seconds to minutes, both in vivo and in vitro, and this stability is related to the age of the cell system under study. It is noteworthy that the residues most essential to enkephalin function are also either neurotransmitters themselves (glycine) or immediate precursors of L-Dopa, dopamine and norepinephrine (tyrosine and phenylalanine). The variable fifth amino acid leucine (leu5) or methionine (met5) has not yet been assigned any neurotransmitter candidacy. Again, this suggests that enkephalin is polyfunctional in that, in its intact state it elicits binding to the same sites in the brain as morphine and other opiates, and its degradation products have a potential for follow-up accessory functions by reacting as signaling entities themselves, or as the immediate precursors to inhibitory or metabotropic neurotransmitters. Enkephalins are present in macrophages infiltrating the dermal papillae in involved psoriatic skin and that the amount of enkephalin is significantly increased in involved psoriatic skin. Major enkephalin pathways in the brain involve the extrapyramidal system, including motor pathways controlled by the basal ganglia, the limbic system that governs emotional and behavioral control, and the hypothalamic-neuroendocrine axis. The apparent overlap of localization within the central nervous system of dopaminergic, glycinergic, and enkephalinergic pathways is speculated to be of neurophysiological significance, especially in light of the relatively short half-life of the enkephalins and the immediate precursor-product relationship between tyrosine and dopamine, and glycinergic signaling. Enkephalins are released into the bloodstream of mammals by the adrenal medulla. Once they are in the blood, these peptides undergo a fairly rapid hydrolysis by several plasma-contained enzymes. However, a fraction of the enkephalins present in the plasma are bound to the serum albumin, and the bound peptides are almost completely intact even after a long incubation in the presence of serum enzymes. (PMID: 9450624, 16802191, 4069309) [HMDB] Enkephalin L is an opioid peptide. Opioid peptides are a group of neuropeptides which include enkephalins, endorphins and dynorphins. In addition to their central and peripheral antinociceptive function, opioids can modulate immune activity and cell proliferation. Enkephalins typically have a turnover rate measured in seconds to minutes, both in vivo and in vitro, and this stability is related to the age of the cell system under study. It is noteworthy that the residues most essential to enkephalin function are also either neurotransmitters themselves (glycine) or immediate precursors of L-Dopa, dopamine and norepinephrine (tyrosine and phenylalanine). The variable fifth amino acid leucine (leu5) or methionine (met5) has not yet been assigned any neurotransmitter candidacy. Again, this suggests that enkephalin is polyfunctional in that, in its intact state it elicits binding to the same sites in the brain as morphine and other opiates, and its degradation products have a potential for follow-up accessory functions by reacting as signaling entities themselves, or as the immediate precursors to inhibitory or metabotropic neurotransmitters. Enkephalins are present in macrophages infiltrating the dermal papillae in involved psoriatic skin and that the amount of enkephalin is significantly increased in involved psoriatic skin. Major enkephalin pathways in the brain involve the extrapyramidal system, including motor pathways controlled by the basal ganglia, the limbic system that governs emotional and behavioral control, and the hypothalamic-neuroendocrine axis. The apparent overlap of localization within the central nervous system of dopaminergic, glycinergic, and enkephalinergic pathways is speculated to be of neurophysiological significance, especially in light of the relatively short half-life of the enkephalins and the immediate precursor-product relationship between tyrosine and dopamine, and glycinergic signaling. Enkephalins are released into the bloodstream of mammals by the adrenal medulla. Once they are in the blood, these peptides undergo a fairly rapid hydrolysis by several plasma-contained enzymes. However, a fraction of the enkephalins present in the plasma are bound to the serum albumin, and the bound peptides are almost completely intact even after a long incubation in the presence of serum enzymes. (PMID: 9450624, 16802191, 4069309). D018377 - Neurotransmitter Agents > D018847 - Opioid Peptides D018377 - Neurotransmitter Agents > D004745 - Enkephalins [Leu5]-Enkephalin is a pentapeptide with morphine like properties. [Leu5]-Enkephalin is a five amino acid endogenous peptide that acts as an agonist at opioid receptors. [Leu5]-Enkephalin is a pentapeptide with morphine like properties. [Leu5]-Enkephalin is a five amino acid endogenous peptide that acts as an agonist at opioid receptors. [Leu5]-Enkephalin is a pentapeptide with morphine like properties. [Leu5]-Enkephalin is a five amino acid endogenous peptide that acts as an agonist at opioid receptors.
Adomeglivant
Butirosina
N-[(5Z)-5-(2,6-Dioxo-1,3-dipropylpurin-8-ylidene)-1-methyl-2H-pyrazol-3-yl]-2-[4-(phenylmethoxy)phenyl]acetamide
Rociletinib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EB - Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
4-[2-Acetylamino-2-(1-biphenyl-4-ylmethyl-2-oxo-azepan-3-ylcarbamoyl)-ethyl]-2-formyl-benzoic acid
scutebarbatine F
A diterpene alkaloid of group of neo-clerodanes isolated from the whole plants of Scutellaria barbata and has been shown to exhibit neoplastic activity.
[6-{(1E,3E)-5-[(2S,3S,5R,6R)-5-{[(2Z,4S)-4-(acetyloxy)pent-2-enoyl]amino}-3,6-dimethyltetrahydro-2H-pyran-2-yl]-3-methylpenta-1,3-dien-1-yl}-4-(chloromethyl)-4-hydroxytetrahydro-2H-pyran-2-yl]acetic acid
(2S,3S,4R,5R)-3,4-dimethyl-2-hydroxyl-5-(4-hydroxyl-4,5-methylenedioxy-6,3,5-trimethoxylbiphenyl-2-yl)tetrahydrofuranyl-8-oxo-1-oxa-3-azaspiro[4.5]dec-2-enyl-2,8-ether|gymnothelignan A
2-amino-5-[(5-beta-D-glucopyranosyl-4-hydroxy-cyclopent-2-enylamino)-methyl]-7-beta-D-ribofuranosyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one
Tyr Ala Phe Arg
Ala Phe Tyr Arg
Glu Arg His Asp
YGGFL
D018377 - Neurotransmitter Agents > D018847 - Opioid Peptides D018377 - Neurotransmitter Agents > D004745 - Enkephalins
Ala Phe Arg Tyr
Ala Arg Phe Tyr
Ala Arg Tyr Phe
Ala Tyr Phe Arg
Ala Tyr Arg Phe
Cys Phe Met Arg
Cys Phe Arg Met
Cys Phe Thr Trp
Cys Phe Trp Thr
Cys Met Phe Arg
Cys Met Arg Phe
Cys Arg Phe Met
Cys Arg Met Phe
Cys Thr Phe Trp
Cys Thr Trp Phe
Cys Trp Phe Thr
Cys Trp Thr Phe
Asp Glu His Arg
Asp Glu Arg His
Asp Phe Phe Lys
Asp Phe Phe Gln
Asp Phe Lys Phe
Asp Phe Gln Phe
Asp His Glu Arg
Asp His Arg Glu
Asp His Val Trp
Asp His Trp Val
Asp Lys Phe Phe
Asp Lys Met Tyr
Asp Lys Tyr Met
Asp Met Lys Tyr
Asp Met Tyr Lys
Asp Gln Phe Phe
Asp Arg Glu His
Asp Arg His Glu
Asp Val His Trp
Asp Val Trp His
Asp Trp His Val
Asp Trp Val His
Asp Tyr Lys Met
Asp Tyr Met Lys
Glu Asp His Arg
Glu Asp Arg His
Glu Phe Phe Asn
Glu Phe Asn Phe
Glu His Asp Arg
Glu His Arg Asp
Glu Asn Phe Phe
Glu Arg Asp His
Phe Ala Arg Tyr
Phe Ala Tyr Arg
Phe Cys Met Arg
Phe Cys Arg Met
Phe Cys Thr Trp
Phe Cys Trp Thr
Phe Asp Phe Lys
Phe Asp Phe Gln
Phe Asp Lys Phe
Phe Asp Gln Phe
Phe Glu Phe Asn
Phe Glu Asn Phe
Phe Phe Asp Lys
Phe Phe Asp Gln
Phe Phe Glu Asn
Phe Phe Gly Trp
Phe Phe Lys Asp
Phe Phe Asn Glu
Phe Phe Gln Asp
Phe Phe Arg Ser
Phe Phe Ser Arg
Phe Phe Trp Gly
Phe Gly Phe Trp
Phe Gly Trp Phe
Phe Ile Asn Tyr
Phe Ile Tyr Asn
Phe Lys Asp Phe
Phe Lys Phe Asp
Phe Lys Met Met
Phe Leu Asn Tyr
Phe Leu Tyr Asn
Phe Met Cys Arg
Phe Met Lys Met
Phe Met Met Lys
Phe Met Met Gln
Phe Met Gln Met
Phe Met Arg Cys
Phe Asn Glu Phe
Phe Asn Phe Glu
Phe Asn Ile Tyr
Phe Asn Leu Tyr
Phe Asn Tyr Ile
Phe Asn Tyr Leu
Phe Gln Asp Phe
Phe Gln Phe Asp
Phe Gln Met Met
Phe Gln Val Tyr
Phe Gln Tyr Val
Phe Arg Ala Tyr
Phe Arg Cys Met
Phe Arg Phe Ser
Phe Arg Met Cys
Phe Arg Ser Phe
Phe Arg Tyr Ala
Phe Ser Phe Arg
Phe Ser Arg Phe
Phe Thr Cys Trp
Phe Thr Trp Cys
Phe Val Gln Tyr
Phe Val Tyr Gln
Phe Trp Cys Thr
Phe Trp Phe Gly
Phe Trp Gly Phe
Phe Trp Thr Cys
Phe Tyr Ala Arg
Phe Tyr Ile Asn
Phe Tyr Leu Asn
Phe Tyr Asn Ile
Phe Tyr Asn Leu
Phe Tyr Gln Val
Phe Tyr Arg Ala
Phe Tyr Val Gln
Gly Phe Phe Trp
Gly Phe Trp Phe
Gly Met Trp Tyr
Gly Met Tyr Trp
Gly Trp Phe Phe
Gly Trp Met Tyr
Gly Trp Tyr Met
Gly Tyr Met Trp
Gly Tyr Trp Met
His Asp Glu Arg
His Asp Arg Glu
His Asp Val Trp
His Asp Trp Val
His Glu Asp Arg
His Glu Arg Asp
His Ile Thr Trp
His Ile Trp Thr
His Leu Thr Trp
His Leu Trp Thr
His Arg Asp Glu
His Arg Glu Asp
His Thr Ile Trp
His Thr Leu Trp
His Thr Trp Ile
His Thr Trp Leu
His Val Asp Trp
His Val Trp Asp
His Trp Asp Val
His Trp Ile Thr
His Trp Leu Thr
His Trp Thr Ile
His Trp Thr Leu
His Trp Val Asp
Ile Phe Asn Tyr
Ile Phe Tyr Asn
Ile His Thr Trp
Ile His Trp Thr
Ile Asn Phe Tyr
Ile Asn Tyr Phe
Ile Thr His Trp
Ile Thr Trp His
Ile Trp His Thr
Ile Trp Thr His
Ile Tyr Phe Asn
Ile Tyr Asn Phe
Lys Asp Phe Phe
Lys Asp Met Tyr
Lys Asp Tyr Met
Lys Phe Asp Phe
Lys Phe Phe Asp
Lys Phe Met Met
Lys Met Asp Tyr
Lys Met Phe Met
Lys Met Met Phe
Lys Met Tyr Asp
Lys Tyr Asp Met
Lys Tyr Met Asp
Leu Phe Asn Tyr
Leu Phe Tyr Asn
Leu His Thr Trp
Leu His Trp Thr
Leu Asn Phe Tyr
Leu Asn Tyr Phe
Leu Tyr Phe Asn
Leu Tyr Asn Phe
Met Cys Phe Arg
Met Cys Arg Phe
Met Asp Lys Tyr
Met Asp Tyr Lys
Met Phe Cys Arg
Met Phe Lys Met
Met Phe Met Lys
Met Phe Met Gln
Met Phe Gln Met
Met Phe Arg Cys
Met Gly Trp Tyr
Met Gly Tyr Trp
Met Lys Asp Tyr
Met Lys Phe Met
Met Lys Met Phe
Met Lys Tyr Asp
Met Met Phe Lys
Met Met Phe Gln
Met Met Lys Phe
Met Met Gln Phe
Met Gln Phe Met
Met Gln Met Phe
Met Arg Cys Phe
Met Arg Phe Cys
Met Arg Ser Tyr
Met Arg Tyr Ser
Met Ser Arg Tyr
Met Ser Tyr Arg
Met Trp Gly Tyr
Met Trp Tyr Gly
Met Tyr Asp Lys
Met Tyr Gly Trp
Met Tyr Lys Asp
Met Tyr Arg Ser
Met Tyr Ser Arg
Met Tyr Trp Gly
Asn Glu Phe Phe
Asn Phe Glu Phe
Asn Phe Phe Glu
Asn Phe Ile Tyr
Asn Phe Leu Tyr
Asn Phe Tyr Ile
Asn Phe Tyr Leu
Asn Ile Phe Tyr
Asn Ile Tyr Phe
Asn Leu Phe Tyr
Asn Leu Tyr Phe
Asn Pro Tyr Tyr
Asn Tyr Phe Ile
Asn Tyr Phe Leu
Asn Tyr Ile Phe
Asn Tyr Leu Phe
Asn Tyr Pro Tyr
Asn Tyr Tyr Pro
Pro Asn Tyr Tyr
Pro Tyr Asn Tyr
Pro Tyr Tyr Asn
Gln Asp Phe Phe
Gln Phe Asp Phe
Gln Phe Phe Asp
Gln Phe Met Met
Gln Phe Val Tyr
Gln Phe Tyr Val
Gln Met Phe Met
Gln Met Met Phe
Gln Val Phe Tyr
Gln Val Tyr Phe
Gln Tyr Phe Val
Gln Tyr Val Phe
Arg Cys Phe Met
Arg Cys Met Phe
Arg Asp Glu His
Arg Asp His Glu
Arg Glu Asp His
Arg Glu His Asp
Arg Phe Cys Met
Arg Phe Met Cys
Arg His Asp Glu
Arg His Glu Asp
Arg Met Cys Phe
Arg Met Phe Cys
Arg Met Ser Tyr
Arg Met Tyr Ser
Arg Ser Met Tyr
Arg Ser Tyr Met
Arg Tyr Met Ser
Arg Tyr Ser Met
Ser Met Arg Tyr
Ser Met Tyr Arg
Ser Arg Met Tyr
Ser Arg Tyr Met
Ser Thr Trp Tyr
Ser Thr Tyr Trp
Ser Trp Thr Tyr
Ser Trp Tyr Thr
Ser Tyr Met Arg
Ser Tyr Arg Met
Ser Tyr Thr Trp
Ser Tyr Trp Thr
Thr Cys Phe Trp
Thr Cys Trp Phe
Thr Phe Cys Trp
Thr Phe Trp Cys
Thr Ser Trp Tyr
Thr Ser Tyr Trp
Thr Trp Cys Phe
Thr Trp Phe Cys
Thr Trp Ser Tyr
Thr Trp Tyr Ser
Thr Tyr Ser Trp
Thr Tyr Trp Ser
Val Asp His Trp
Val Asp Trp His
Val Phe Gln Tyr
Val Phe Tyr Gln
Val His Asp Trp
Val His Trp Asp
Val Gln Phe Tyr
Val Gln Tyr Phe
Val Trp Asp His
Val Trp His Asp
Val Tyr Phe Gln
Val Tyr Gln Phe
Trp Cys Phe Thr
Trp Cys Thr Phe
Trp Asp His Val
Trp Asp Val His
Trp Phe Cys Thr
Trp Phe Phe Gly
Trp Phe Gly Phe
Trp Phe Thr Cys
Trp Gly Phe Phe
Trp Gly Met Tyr
Trp Gly Tyr Met
Trp His Asp Val
Trp His Val Asp
Trp Met Gly Tyr
Trp Met Tyr Gly
Trp Ser Thr Tyr
Trp Ser Tyr Thr
Trp Thr Cys Phe
Trp Thr Phe Cys
Trp Thr Ser Tyr
Trp Thr Tyr Ser
Trp Val Asp His
Trp Val His Asp
Trp Tyr Gly Met
Trp Tyr Met Gly
Trp Tyr Ser Thr
Trp Tyr Thr Ser
Tyr Asp Lys Met
Tyr Asp Met Lys
Tyr Phe Ile Asn
Tyr Phe Leu Asn
Tyr Phe Asn Ile
Tyr Phe Asn Leu
Tyr Phe Gln Val
Tyr Phe Val Gln
Tyr Gly Met Trp
Tyr Gly Trp Met
Tyr Ile Phe Asn
Tyr Ile Asn Phe
Tyr Lys Asp Met
Tyr Lys Met Asp
Tyr Leu Phe Asn
Tyr Leu Asn Phe
Tyr Met Asp Lys
Tyr Met Gly Trp
Tyr Met Lys Asp
Tyr Met Arg Ser
Tyr Met Ser Arg
Tyr Met Trp Gly
Tyr Asn Phe Ile
Tyr Asn Phe Leu
Tyr Asn Ile Phe
Tyr Asn Leu Phe
Tyr Asn Pro Tyr
Tyr Asn Tyr Pro
Tyr Pro Asn Tyr
Tyr Pro Tyr Asn
Tyr Gln Phe Val
Tyr Gln Val Phe
Tyr Arg Met Ser
Tyr Arg Ser Met
Tyr Ser Met Arg
Tyr Ser Arg Met
Tyr Ser Thr Trp
Tyr Ser Trp Thr
Tyr Thr Ser Trp
Tyr Thr Trp Ser
Tyr Val Phe Gln
Tyr Val Gln Phe
Tyr Trp Gly Met
Tyr Trp Met Gly
Tyr Trp Ser Thr
Tyr Trp Thr Ser
Tyr Tyr Asn Pro
Tyr Tyr Pro Asn
Adomeglivant
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent
(T-4)-Difluoro[6-(2,4,6-trimethylphenyl)-N-[6-(2,4,6-trimethylphenyl)-2(1H)-quinolinylidene]-2-quinolinaminato]boron
Rucaparib Camsylate
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C62554 - Poly (ADP-Ribose) Polymerase Inhibitor C471 - Enzyme Inhibitor
propyl 3-O-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-2-O-(alpha-L-rhamnopyranosyl)-alpha-L-rhamnopyranoside
N-(Ethylsulfonyl)tryptophyl-N~1~-{4-[amino(imino)methyl]benzyl}glutamamide
4-[2-Acetylamino-2-(1-biphenyl-4-ylmethyl-2-oxo-azepan-3-ylcarbamoyl)-ethyl]-2-formyl-benzoic acid
Rociletinib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EB - Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
(7,7-Dimethyl-2-oxo-1-bicyclo[2.2.1]heptanyl)methanesulfonic acid;6-fluoro-2-[4-(methylaminomethyl)phenyl]-3,10-diazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraen-9-one
(2R)-3-hydroxy-2-{[6-O-(6-O-octanoyl-alpha-D-glucopyranosyl)-alpha-D-glucopyranosyl]oxy}propanoate
[(2S,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4-amino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-hydroxy-5-methyl-4-(methylamino)oxan-3-yl] dihydrogen phosphate
(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-[[(1S,2R,4R,7Z,11S)-4,8-dimethyl-13-oxo-3,14-dioxatricyclo[9.3.0.02,4]tetradec-7-en-12-yl]methylsulfanyl]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
4-amino-N-[(1R,2S,3R,4R,5S)-5-amino-4-[[(3R,4R,5S,6R)-3-amino-6-(aminomethyl)-4,5-dihydroxy-2-oxanyl]oxy]-3-[[(3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-oxolanyl]oxy]-2-hydroxycyclohexyl]-2-hydroxybutanamide
N-[[(8S,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methyl-4-phenylbenzenesulfonamide
N-[[(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methyl-4-phenylbenzenesulfonamide
N-[[(8S,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methyl-4-phenylbenzenesulfonamide
N-[[(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methyl-4-phenylbenzenesulfonamide
3-cyclohexyl-1-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-2-phenylethenyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-cyclohexyl-1-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-2-phenylethenyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methylurea
2-O-[6-O-Octanoyl-alpha-D-glucopyranosyl-(1->6)-alpha-D-glucopyranosyl]-D-glycerate
3-cyclohexyl-1-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-2-phenylethenyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-cyclohexyl-1-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-2-phenylethenyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-cyclohexyl-1-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-2-phenylethenyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-(4-fluorophenyl)-1-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-cyclohexyl-1-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-2-phenylethenyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-(4-fluorophenyl)-1-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea
1-(3,5-dimethyl-1,2-oxazol-4-yl)-3-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3,3,3-trifluoropropyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
3-cyclohexyl-1-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-2-phenylethenyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-cyclohexyl-1-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-2-phenylethenyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-(4-fluorophenyl)-1-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-(4-fluorophenyl)-1-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-(4-fluorophenyl)-1-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-(4-fluorophenyl)-1-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-(4-fluorophenyl)-1-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-(4-fluorophenyl)-1-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea
1-(3,5-dimethyl-4-isoxazolyl)-3-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3,3,3-trifluoropropyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
(3R)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-N-(pyridin-4-ylmethyl)-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide
N-[[(4R,5R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridin-4-ylacetamide
N-[[(4S,5S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridin-4-ylacetamide
N-[[(4S,5R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridin-4-ylacetamide
N-[[(4R,5S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridin-4-ylacetamide
N-[[(4S,5R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridin-4-ylacetamide
N-[[(4S,5S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridin-4-ylacetamide
N-[[(4R,5R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridin-4-ylacetamide
N-[[(4R,5S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridin-4-ylacetamide
1-(3,5-dimethyl-4-isoxazolyl)-3-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3,3,3-trifluoropropyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3,5-dimethyl-4-isoxazolyl)-3-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3,3,3-trifluoropropyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3,5-dimethyl-4-isoxazolyl)-3-[(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3,3,3-trifluoropropyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3,5-dimethyl-4-isoxazolyl)-3-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3,3,3-trifluoropropyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3,5-dimethyl-4-isoxazolyl)-3-[(4R,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3,3,3-trifluoropropyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3,5-dimethyl-4-isoxazolyl)-3-[(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3,3,3-trifluoropropyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
(3S)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-N-(pyridin-4-ylmethyl)-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide
2-O-demethyl-beta-anthrosyl-(1->3)-alpha-L-rhamnosyl-(1->3)-alpha-L-rhamnose
butirosin A
A butirosin that consists of neamine in which is substituted at position 2 by a beta-D-xylofuranosyl and at position 4 by an (S)-2-hydroxy-4-aminobutyryl group. D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents
Leu-Enkephalin
A pentapeptide comprising L-tyrosine, glycine, glycine, L-phenylalanine and L-leucine residues joined in sequence by peptide linkages. It is an endogenous opioid peptide produced in vertebrate species, including rodents, primates and humans that results from decomposition of proenkephalin or dynorphin and exhibits antinociceptive properties.
3-vinylbacteriochlorophyllide d(1-)
A cyclic tetrapyrrole anion that is the conjugate base of 3-vinylbacteriochlorophyllide d, obtained by deprotonation of the carboxy group; major species at pH 7.3.
Leu-enkephalin zwitterion
A peptide zwitterion obtained by transfer of a proton from the carboxy to the amino terminus of Leu-enkephalin. Major species at pH 7.3.